Exploring the pathogenesis and treatment of IgA nephropathy based on epigenetics

被引：2
作者：
Zhang, Yunfan [1 ,2 ]
Yang, Huanhuan [1 ,2 ]
Jiang, Ming [1 ,2 ]
Nie, Xiaojing [1 ,2 ,3 ]
机构：
[1] Fujian Med Univ, Fuzong Clin Med Coll, Fuzhou 350025, Peoples R China
[2] 900th Hosp Joint Logist Support Force, Dept Gynecol & Obstet, PLA, Fuzhou 350025, Fujian, Peoples R China
[3] Xiamen Univ, Affiliated Dongfang Hosp, Dept Pediat, Fuzhou 350025, Fujian, Peoples R China
来源：
EPIGENOMICS | 2023年 / 15卷 / 19期
基金：
中国国家自然科学基金;
关键词：
epigenetic; histone modifications; IgA nephropathy; methylation; miRNAs; pathogenesis; treatment; DNA METHYLATION; T-CELLS; EXPRESSION; MIR-148B;
D O I：
10.2217/epi-2023-0318
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
IgA nephropathy is the most common primary glomerulonephritis worldwide. However, its exact cause remains unclear, with known genetic factors explaining only 11% of the variation. Recently, researchers have turned their attention to epigenetic abnormalities in immune-related diseases, recognizing their significance in IgA nephropathy's development and progression. This emerging field has revolutionized our understanding of epigenetics in IgA nephropathy research. Though in its early stages, studying IgA nephropathy's epigenetics holds promise for unraveling its pathogenesis and identifying new biomarkers and therapies. This review aims to comprehensively analyze epigenetics' role in IgA nephropathy's development and suggest avenues for potential therapeutic interventions. In the future, assessing and modulating epigenetics may become integral in diagnosing, tailoring treatments and assessing prognoses for IgA nephropathy. Epigenetics is involved in the occurrence and development of IgA nephropathy.
引用
收藏
页码：1017 / 1026
页数：10
相关论文
共 50 条
  • [21] Towards a personalized treatment for IgA nephropathy considering pathology and pathogenesis
    Coppo, Rosanna
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 (11) : 1832 - 1838
  • [22] Progress in understanding the pathogenesis of IgA nephropathy: New perspectives for the near future?
    Segarra, A.
    [J]. NEFROLOGIA, 2010, 30 (05): : 501 - 507
  • [23] IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy
    Novak, Jan
    Julian, Bruce A.
    Tomono, Milan
    Mestecky, Jiri
    [J]. SEMINARS IN NEPHROLOGY, 2008, 28 (01) : 78 - 87
  • [24] Treatment controversies for IgA nephropathy
    Almartine, E.
    de Ligny, B. Hurault
    [J]. NEPHROLOGIE & THERAPEUTIQUE, 2007, 3 : S201 - S205
  • [25] Treatment of childhood IgA nephropathy
    Yoshikawa, N
    Ito, H
    [J]. NEPHROLOGY, 1997, 3 : S735 - S738
  • [26] An update on the treatment of IgA nephropathy
    Barbour, Sean
    Feehally, John
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2017, 26 (04) : 319 - 326
  • [27] Treatment of IgA nephropathy in children
    Yoshikawa, N
    [J]. NEPHROLOGY, 2002, 7 : S164 - S165
  • [28] Glycosylation of IgA1 and pathogenesis of IgA nephropathy
    Jan Novak
    Bruce A. Julian
    Jiri Mestecky
    Matthew B. Renfrow
    [J]. Seminars in Immunopathology, 2012, 34 : 365 - 382
  • [29] Glycosylation of IgA1 and pathogenesis of IgA nephropathy
    Novak, Jan
    Julian, Bruce A.
    Mestecky, Jiri
    Renfrow, Matthew B.
    [J]. SEMINARS IN IMMUNOPATHOLOGY, 2012, 34 (03) : 365 - 382
  • [30] New Insights into the Pathogenesis of IgA Nephropathy
    Novak, Jan
    Rizk, Dana
    Takahashi, Kazuo
    Zhang, XianWen
    Bian, Qi
    Ueda, Hiroyuki
    Ueda, Yoshimi
    Reily, Colin
    Lai, Ling-Yun
    Hao, Chuanming
    Novak, Lea
    Huang, Zhi-Qiang
    Renfrow, Matthew B.
    Suzuki, Hitoshi
    Julian, Bruce A.
    [J]. KIDNEY DISEASES, 2015, 1 (01) : 8 - 18
12345